BAŞKENT ÜNİVERSİTESİ
Eczacılık Fakültesi

 

2020-2021 YAYINLARIMIZ

Laban, A., Birand, N., Chukwunyere, U., Abdi, A., & Basgut, B. (2021).Evaluation of drug-drug interactions in cancer patients treated at auniversity hospital in North Cyprus using two interaction databases. Nigerian Journal of Clinical Practice, 24(7), 1067.

Aktas, Y., Celik Tekeli, M., & Celebi, N. (2020). Development and characterization of exendin-4 loaded selfnanoemulsifying system and in vitro evaluation on Caco-2 cell line. Journal of Microencapsulation, 37(1), 41-51.

Amasya, G., Ozturk, C., Aksu, B., & Tarimci, N. (2021). QbD based formulationoptimization of semi-solid lipid nanoparticles as nano-cosmeceuticals. Journal of Drug Delivery Science andTechnology, 66, 102737.

Celik-Tekeli, M., Celebi, N., Tekeli, M. Y., & Aktas, Y. (2021). Evaluation of the hypoglycemic effect of exendin-4?s new oral selfnanoemulsifying system in rats. European Journal of Pharmaceutical Sciences, 158, 105644.

Çelebier, M., Dogan, A., Süslü, Í., & Altınöz, S. (2021). Electrochemical Behaviorand Square-Wave Stripping Voltammetric Determination of Roflumilast in Pharmaceutical Dosage Forms. Combinatorial Chemistry & High Throughput Screening, 24(3), 400-408.

Karakucuk, A., & Celebi, N. (2020). Investigation of formulation and processparameters of wet media milling to develop etodolacnanosuspensions. Pharmaceutical Research, 37, 1-18.

Karakucuk, A., Tort, S., Han, S., Oktay, A. N., & Celebi, N. (2021). Etodolacnanosuspension based gel for enhanced dermal delivery: in vitro and in vivo evaluation. Journal ofMicroencapsulation, 38(4), 218-232.

Mutlu-Agardan, N. B., Yilmaz, S., Kaynak Onurdag, F., & Celebi, N. (2021). Development of effective AmB/AmB??CD complex double loaded liposomes using a factorial design for systemic fungal infection treatment. Journal of liposome research, 31(2), 177-188.

Oktay, A. N., Ilbasmis-Tamer, S., Han, S., Uludag, O., & Celebi, N. (2020). Preparation and in vitro/in vivo evaluation of flurbiprofennanosuspension-based gel for dermal application. European Journal of Pharmaceutical Sciences, 155, 105548.

Oktay, A. N., Ilbasmis-Tamer, S., Karakucuk, A., & Celebi, N. (2020). Screening of stabilizing agents to optimize flurbiprofennanosuspensions using experimental design. Journal ofDrug DeliveryScience and Technology, 57, 101690.

Oktay, A. N., Ilbasmis-Tamer, S., Uludag, O., & Celebi, N. (2021). Enhanced Dermal Delivery of Flurbiprofen Nanosuspension Based Gel: Development and Ex Vivo Permeation, Pharmacokinetic Evaluations. Pharmaceutical Research, 1-19.

Tashan, E., Karakucuk, A., & Celebi, N. (2020). Development of
nanocrystal ziprasidone orally disintegrating tablets: optimization by usingdesign of experiment and in vitroevaluation. AAPSPharmSciTech, 21(3), 1-12.

Tekeli, M. C., Aktas, Y., & Celebi, N. (2021). Oral self-nanoemulsifyingformulation of GLP-1 agonist peptide exendin-4: development, characterization and permeability assesment on Caco2 cell monolayer. Amino Acids, 53(1), 73-88.

Amasya, G., TÜrk, C. T. Ş., Badilli, U., & Tarimci, N. (2020). Development and statistical optimization of solid lipid nanoparticle formulations of fluticasone propionate. Turkish Journal of Pharmaceutical Sciences, 17(4), 359.

BACANLI, M., DİLSİZ, S. A., BAŞARAN, A., & BAŞARAN, N. Phytochemicals Used in Autoimmune Disorders. Hacettepe University Journal of the Faculty of Pharmacy, 40(2), 83-92.

Karakucuk, A., Ozturk, N., & Celebi, N. (2020). Evaluation of Caco-2 cell permeability of ritonavir nanosuspensions. Journal of the Faculty of Pharmacy of Istanbul University, 50(3), 251-256.

Karaküçük, A., Taşhan, E., Öztürk, N., & Celebi, N. (2021). In Vitro Caco-2 Cell Permeability Studies of Ziprasidone Hydrochloride Monohydrate Nanocrystals. Turkish Journal of Pharmaceutical Sciences, 18(2), 223.

KOÇAK, E., & ALTINÖZ, S. (2020). Evaluation of regular UPLC/MS system for experimental and clinical proteomics. Journal Of Research In Pharmacy, cilt.24, sa.4, ss.582-592.

SÜSLÜ, İ., ERDOĞAN KABLAN, S., Safak, O., & ŞİMŞEK, R. (2021). Electrochemical detection of antioxidant activities of 4-indolyl-5-oxo6, 6 (or 7, 7)-dimethyl-1, 4, 5, 6, 7, 8hexahydroquinolinederivatives. Journal Of Research In Pharmacy cilt.25, sa.1, ss.52-62, 2021

A.Gürbay,B.Koçer Gümüşel,H.Özgüneş,"Ksenobiyotiklerin Organizmadaki Yazgısı:Toksikokinetik",Toksikoloji, Hacettepe Üniversitesi Yayınları:71-119(2020)

H.Özgüneş,Ü.Ündeğer Bucurgat,N.Başaran,"Genetik Polimorfizm ve Toksikolojik Sonuçları" Toksikoloji, Hacettepe Üniversitesi Yayınları:285-299(2020)

S.Sabuncuoğlu,H.Özgüneş,"Etkileşmeler ve Toksikolojik Sonuçları, "Toksikoloji, Hacettepe Üniversitesi Yayınları:299-327(2020)